Assenagon Asset Management S.A. Boosts Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

Assenagon Asset Management S.A. lifted its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 814.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 223,704 shares of the company's stock after acquiring an additional 199,245 shares during the period. Assenagon Asset Management S.A. owned 0.62% of Keros Therapeutics worth $12,990,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Keros Therapeutics during the 2nd quarter valued at approximately $128,000. Ameritas Investment Partners Inc. increased its holdings in Keros Therapeutics by 14.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company's stock valued at $169,000 after acquiring an additional 324 shares during the last quarter. Quest Partners LLC increased its holdings in Keros Therapeutics by 23,945.0% in the 2nd quarter. Quest Partners LLC now owns 4,809 shares of the company's stock valued at $220,000 after acquiring an additional 4,789 shares during the last quarter. XTX Topco Ltd bought a new stake in Keros Therapeutics in the 2nd quarter valued at $228,000. Finally, Bayesian Capital Management LP purchased a new stake in Keros Therapeutics in the 1st quarter worth $267,000. Hedge funds and other institutional investors own 71.56% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on KROS. Cantor Fitzgerald began coverage on Keros Therapeutics in a research report on Thursday. They set an "overweight" rating for the company. Bank of America cut their price target on Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating for the company in a report on Thursday, September 12th. Guggenheim began coverage on Keros Therapeutics in a report on Monday, September 23rd. They set a "buy" rating and a $96.00 price objective on the stock. Finally, Scotiabank initiated coverage on Keros Therapeutics in a research report on Wednesday, October 16th. They set a "sector outperform" rating and a $77.00 target price for the company. Eleven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Keros Therapeutics presently has an average rating of "Buy" and a consensus target price of $89.11.

Keros Therapeutics Trading Down 0.0 %

NASDAQ:KROS traded down $0.03 during midday trading on Monday, hitting $60.73. 302,359 shares of the company traded hands, compared to its average volume of 368,907. The firm has a market capitalization of $2.28 billion, a P/E ratio of -11.84 and a beta of 1.23. The firm's fifty day moving average is $54.91 and its 200-day moving average is $51.83. Keros Therapeutics, Inc. has a 12-month low of $27.31 and a 12-month high of $73.00.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($1.25) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.02). The firm had revenue of $0.04 million for the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. During the same quarter last year, the business earned ($1.27) EPS. On average, research analysts expect that Keros Therapeutics, Inc. will post -4.88 EPS for the current fiscal year.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, Director Carl L. Gordon sold 250,000 shares of the firm's stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the sale, the director now owns 119,522 shares of the company's stock, valued at $5,260,163.22. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 22.90% of the stock is currently owned by insiders.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.